• Something wrong with this record ?

Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease

AM. Carranza-Trejo, V. Vetvicka, L. Vistejnova, M. Kralickova, EB. Montufar

. 2021 ; 15 (7) : 783-796. [pub] 20210218

Language English Country Great Britain

Document type Journal Article, Review

Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most widespread chronic liver disease in the world. It can evolve into nonalcoholic steatohepatitis (NASH) where inflammation and hepatocyte ballooning are key participants in the determination of this steatotic state.Areas covered: To provide a systematic overview and current understanding of the role of inflammation in NAFLD and its progression to NASH, the function of the cells involved, and the activation pathways of the innate immunity and cell death; resulting in inflammation and chronic liver disease. A PubMed search was made with relevant articles together with relevant references were included for the writing of this review.Expert opinion: Innate and adaptive immunity are the key players in the NAFLD progression; some of the markers presented during NAFLD are also known to be immunity biomarkers. All cells involved in NAFLD and NASH are known to have immunoregulatory properties and their imbalance will completely change the cytokine profile and form a pro-inflammatory microenvironment. It is necessary to fully answer the question of what initiators and metabolic imbalances are particularly important, considering sterile inflammation as the architect of the disease. Due to the shortage of elucidation of NASH progression, we discuss in this review, how inflammation is a key part of this development and we presume the targets should lead to inflammation and oxidative stress treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004134
003      
CZ-PrNML
005      
20220127145502.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/17474124.2021.1887730 $2 doi
035    __
$a (PubMed)33557653
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Carranza-Trejo, Azalia Mariel $u Biomedical Centre, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic
245    10
$a Hepatocyte and immune cell crosstalk in non-alcoholic fatty liver disease / $c AM. Carranza-Trejo, V. Vetvicka, L. Vistejnova, M. Kralickova, EB. Montufar
520    9_
$a Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most widespread chronic liver disease in the world. It can evolve into nonalcoholic steatohepatitis (NASH) where inflammation and hepatocyte ballooning are key participants in the determination of this steatotic state.Areas covered: To provide a systematic overview and current understanding of the role of inflammation in NAFLD and its progression to NASH, the function of the cells involved, and the activation pathways of the innate immunity and cell death; resulting in inflammation and chronic liver disease. A PubMed search was made with relevant articles together with relevant references were included for the writing of this review.Expert opinion: Innate and adaptive immunity are the key players in the NAFLD progression; some of the markers presented during NAFLD are also known to be immunity biomarkers. All cells involved in NAFLD and NASH are known to have immunoregulatory properties and their imbalance will completely change the cytokine profile and form a pro-inflammatory microenvironment. It is necessary to fully answer the question of what initiators and metabolic imbalances are particularly important, considering sterile inflammation as the architect of the disease. Due to the shortage of elucidation of NASH progression, we discuss in this review, how inflammation is a key part of this development and we presume the targets should lead to inflammation and oxidative stress treatment.
650    _2
$a adaptivní imunita $x imunologie $7 D056704
650    _2
$a progrese nemoci $7 D018450
650    _2
$a hepatocyty $x imunologie $x fyziologie $7 D022781
650    _2
$a lidé $7 D006801
650    _2
$a přirozená imunita $x imunologie $7 D007113
650    _2
$a zánět $x imunologie $x patofyziologie $7 D007249
650    _2
$a Kupfferovy buňky $x imunologie $7 D007728
650    _2
$a lymfocyty $x imunologie $7 D008214
650    _2
$a nealkoholová steatóza jater $x imunologie $x patofyziologie $7 D065626
650    _2
$a oxidační stres $x imunologie $7 D018384
650    _2
$a interakce mezi receptory a ligandy $x imunologie $x fyziologie $7 D020239
650    _2
$a regulovaná buněčná smrt $x imunologie $x fyziologie $7 D000079404
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Vetvicka, Vaclav $u Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA
700    1_
$a Vistejnova, Lucie $u Biomedical Centre, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Kralickova, Milena $u Biomedical Centre, Medical Faculty in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Montufar, Edgar B $u Central European Institute of Technology, Brno University of Technology, Brno, Czech Republic
773    0_
$w MED00174418 $t Expert review of gastroenterology & hepatology $x 1747-4132 $g Roč. 15, č. 7 (2021), s. 783-796
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33557653 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145458 $b ABA008
999    __
$a ok $b bmc $g 1751564 $s 1155283
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 15 $c 7 $d 783-796 $e 20210218 $i 1747-4132 $m Expert review of gastroenterology & hepatology $n Expert Rev Gastroenterol Hepatol $x MED00174418
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...